Shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) have earned a consensus recommendation of “Buy” from the fourteen research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $82.30.
TRHC has been the subject of several research analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $99.00 price objective on shares of Tabula Rasa HealthCare in a research note on Thursday, February 28th. Zacks Investment Research lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. BidaskClub raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Friday, March 22nd. ValuEngine lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Finally, Guggenheim initiated coverage on Tabula Rasa HealthCare in a research note on Wednesday, April 17th. They set a “neutral” rating and a $58.00 price target for the company.
In other news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.50, for a total value of $436,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Calvin H. Knowlton sold 8,270 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total value of $443,933.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,270 shares of company stock valued at $2,565,774. Corporate insiders own 14.00% of the company’s stock.
NASDAQ:TRHC traded up $1.19 during trading hours on Thursday, hitting $47.18. 4,961 shares of the company’s stock traded hands, compared to its average volume of 387,589. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of 138.62 and a beta of 1.51. Tabula Rasa HealthCare has a 52 week low of $42.29 and a 52 week high of $91.16. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.73 and a current ratio of 1.80.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). The company had revenue of $60.96 million during the quarter, compared to analyst estimates of $59.24 million. Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. Equities analysts forecast that Tabula Rasa HealthCare will post -0.55 earnings per share for the current fiscal year.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.